Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

BLAZE-1 phase 3 combo, 2021
 
NCT04427501
RCTbamlanivimab plus etesevimabplaceboCOVID 19 outpatientssome concern
518/517 suggested
  • suggested 71 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 95 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
BLAZE-1 phase 2 Combination with etesevimab, 2020
 
NCT04427501
RCTbamlanivimab plus etesevimabplaceboCOVID 19 outpatientssome concern
112/156 inconclusive
    decreased SARS-CoV-2 log viral load at day 11 compared withplacebo of –0.57 [95% CI, –1.00 to –0.14], P = .01
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).